Kerryn Reding

Feb 12, 2024 | ahajournals.org | Kerryn Reding |Jennifer Jordan

REFERENCES1. Khedagi AM, Bello NA. Hypertensive disorders of pregnancy.Cardiol Clin. 2021; 39:77–90. doi: 10.1016/j.ccl.2020.09.005CrossrefMedlineGoogle Scholar2. Azeez O, Kulkarni A, Kuklina EV, Kim SY, Cox S. Hypertension and diabetes in non-pregnant women of reproductive age in the United States.Prev Chronic Dis. 2019; 16:E146. doi: 10.5888/pcd16.190105CrossrefMedlineGoogle Scholar3. Cameron NA, Petito LC, Shah NS, Perak AM, Catov JM, Bello NA, Capewell S, O’Flaherty M, Lloyd-Jones DM, Greenland P, .

Jan 22, 2024 | radcliffecardiology.com | Wendy Bottinor |Oxana Palesh |Kerryn Reding |Dan Lenihan

Overview Battling cancer is an arduous journey and the impact on one's overall well-being extends beyond the initial diagnosis and treatment.

Jun 1, 2023 | jacc.org | Alexander Lucas |Ralph B. D’Agostino |Jennifer Jordan |Kerryn Reding

Introduction Ascending (AAD) and descending (DAD) thoracic aorta distensibility, and thoracic aorta pulse wave velocity (PWV) reflect vascular stiffening that associates independently with subsequent cardiovascular (CV) events.1 Four to 6 months following cardiotoxic chemotherapy, AAD decreases and PWV increases.2,3 The goal of this prespecified secondary analysis of a previously published4 randomized trial, conducted in collaboration with the Wake Forest NCI Community Oncology Research...

Jun 1, 2023 | jacc.org | Moriah P. Bellissimo |Kerryn Reding |Nathaniel O’Connell |Ralph B. D’Agostino

JACC Journals › JACC: CardioOnc › Archives › Vol. 5 No. 3 IntroductionCancer survivors who received anthracycline-based chemotherapy (ANTH) are at increased risk of cancer therapy–related cardiovascular dysfunction and reduced left ventricular ejection fraction (LVEF), contributing to a heightened risk of developing heart failure (HF).

May 19, 2023 | journals.plos.org | Claire J Han |Kerryn Reding |Matthew Kalady |Rachel L. Yung

Loading metrics Open Access Peer-reviewedResearch Article AbstractPurposeColorectal cancer (CRC) survivors often experience long-term symptoms after cancer treatments. But gastrointestinal (GI) symptom experiences are under-investigated in CRC survivors. We described persistent GI symptoms after cancer treatments in female CRC survivors and assessed GI symptoms’ risk and life-impact factors.